GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Takeda Pharmaceutical Co Ltd (SSE:4502) » Definitions » Owner Earnings per Share (TTM)

Takeda Pharmaceutical Co (SSE:4502) Owner Earnings per Share (TTM) : 145.81 (As of Mar. 2024)


View and export this data going back to . Start your Free Trial

What is Takeda Pharmaceutical Co Owner Earnings per Share (TTM)?

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

Takeda Pharmaceutical Co's Owner Earnings per Share (TTM) ended in Mar. 2024 was 円145.81. It's Price-to-Owner-Earnings ratio for today is 29.49.


The historical rank and industry rank for Takeda Pharmaceutical Co's Owner Earnings per Share (TTM) or its related term are showing as below:

SSE:4502' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 4.7   Med: 14.09   Max: 83.63
Current: 29.49


During the past 13 years, the highest Price-to-Owner-Earnings ratio of Takeda Pharmaceutical Co was 83.63. The lowest was 4.70. And the median was 14.09.


SSE:4502's Price-to-Owner-Earnings is ranked worse than
51.07% of 419 companies
in the Drug Manufacturers industry
Industry Median: 27.85 vs SSE:4502: 29.49

Takeda Pharmaceutical Co's Earnings per Share (Diluted) for the three months ended in Mar. 2024 was 円-2.01. Its Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was 円91.31. It's PE Ratio ratio for today is 47.09.

Takeda Pharmaceutical Co's EPS without NRI for the three months ended in Mar. 2024 was 円-2.01. Its EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2024 was 円91.31. It's PE Ratio without NRI ratio for today is 47.09.


Takeda Pharmaceutical Co Owner Earnings per Share (TTM) Historical Data

The historical data trend for Takeda Pharmaceutical Co's Owner Earnings per Share (TTM) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Takeda Pharmaceutical Co Owner Earnings per Share (TTM) Chart

Takeda Pharmaceutical Co Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Owner Earnings per Share (TTM)
Get a 7-Day Free Trial Premium Member Only Premium Member Only 336.98 725.62 526.27 481.01 143.93

Takeda Pharmaceutical Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Owner Earnings per Share (TTM) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 481.01 487.40 389.85 236.15 143.93

Competitive Comparison of Takeda Pharmaceutical Co's Owner Earnings per Share (TTM)

For the Drug Manufacturers - Specialty & Generic subindustry, Takeda Pharmaceutical Co's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Takeda Pharmaceutical Co's Price-to-Owner-Earnings Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Takeda Pharmaceutical Co's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where Takeda Pharmaceutical Co's Price-to-Owner-Earnings falls into.



Takeda Pharmaceutical Co Owner Earnings per Share (TTM) Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

To make it simple, then you will have:

Owner Earnings per Share (TTM) = (Net Income + Depreciation, Depletion and Amortization + Change In Deferred Tax - 5Y Average of Maintenance Capital Expenditure + Change In Working Capital) / Shares Outstanding (Diluted Average)

Takeda Pharmaceutical Co's Owner Earnings per Share (TTM) Calculation:

TTM / Last Quarter Average of Last 20 Quarters
Net Income 144,067
Depreciation, Depletion and Amortization 728,002
Change In Deferred Tax -91,406
5Y Average of Maintenance Capital Expenditure 299,970
Change In Working Capital -256,003
Shares Outstanding (Diluted Average) 1,605

1. Start with "Net Income" from income statement. Takeda Pharmaceutical Co's Net Income for the trailing twelve months (TTM) ended in Mar. 2024 was 円144,067 Mil.

2. "Depreciation, Depletion and Amortization" is from cashflow statement. Takeda Pharmaceutical Co's Depreciation, Depletion and Amortization for the trailing twelve months (TTM) ended in Mar. 2024 was 円728,002 Mil. This needs to be added back because company does not actually need to pay cash for it. It is a non-cash item.

3. Other non-cash charges usually include "Stock Based Compensation" and "Change In Deferred Tax":
However, to be conservative, GuruFocus will not add Stock Based Compensation back to net income. Takeda Pharmaceutical Co's Change In Deferred Tax for the trailing twelve months (TTM) ended in Mar. 2024 was 円-91,406 Mil.

4. Average maintenance capital expenditure over a business/industry cycle: 5-Year Average Maintenance Capital Expenditure = 円299,970 Mil

It is usually best to take a long-term average of maintenance capital expenditure. Ideally this would be as long as 10 years and include at least one economic downturn. However, since many companies do not have as long as 10-year history, here GuruFocus uses the latest 5 years data to do the calculation. To smooth out unusual years but reflect recent developments, we take an average of the 5 year maintenance capital expenditure.

The following shows how to get maintenance capital expenditure.

First, calculate the revenue change regarding to the previous quarter. If the revenue decreased from the previous quarter, then the Maintenance Capital Expenditure = Capital Expenditure (positive).
Second, if the revenue increased from the previous quarter, then calculate the percentage of Net PPE as of corresponding Revenue.
Growth Capital Expenditure = Percentage of Property, Plant and Equipment as of corresponding Revenue * Revenue Increase
Third, calculate Capital Expenditure (positive) - Growth Capital Expenditure.
If [Capital Expenditure (positive) - Growth Capital Expenditure] was negative, then the Maintenance Capital Expenditure = Capital Expenditure (positive).
If [Capital Expenditure (positive) - Growth Capital Expenditure] was positive, then the Maintenance Capital Expenditure = Capital Expenditure (positive) - Growth Capital Expenditure.
Fourth, get the average of the 5 years maintenance capital expenditure.

Takeda Pharmaceutical Co's 5-Year Average Maintenance Capital Expenditure = 円299,970 Mil

5. "Change In Working Capital" is from cashflow statement. Takeda Pharmaceutical Co's Change In Working Capital for the trailing twelve months (TTM) ended in Mar. 2024 was 円-256,003 Mil.
Note: GuruFocus' Change in Working Capital is provided by Morningstar. It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement from original financial report. And sometimes it includes non-current parts of assets and liabilities.

6. Takeda Pharmaceutical Co's Shares Outstanding (Diluted Average) for the months ended in Mar. 2024 was 1604.823 Mil.

Takeda Pharmaceutical Co's Onwer Earnings Per Share for Mar. 2024 is calculated as:

Owner Earnings per Share (TTM)
=( Net Income+Depreciation, Depletion and Amortization+Change In Deferred Tax
=( 144067 +728002+-91406
-5Y Avg of Maintenance CAPEX+Change In Working Capital )/Shares Outstanding (Diluted Average)
-299970.35027511+-256003)/1604.823
=145.81

Price-to-Owner-Earnings=Current Price/Owner Earnings per Share (TTM)
=4300.00/145.81
=29.49

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Assumption: Companies usually do not report maintenance capital expenditures and growth capital expenditures separately. Here we use estimated numbers and average them over 5 years. The method to estimate maintenance capital expenditures can be found in above part 4.

Note: GuruFocus' Change In Working Capital is provided by Morningstar. It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement from original financial report. And it includes non-current parts of assets and liabilities.


Takeda Pharmaceutical Co Owner Earnings per Share (TTM) Related Terms

Thank you for viewing the detailed overview of Takeda Pharmaceutical Co's Owner Earnings per Share (TTM) provided by GuruFocus.com. Please click on the following links to see related term pages.


Takeda Pharmaceutical Co (SSE:4502) Business Description

Address
1-1, Nihonbashi-Honcho 2-Chome, Chuo-ku, Tokyo, JPN, 103-8668
Takeda Pharmaceutical is Japan's largest pharmaceutical company, with revenue of JPY 4 trillion in fiscal 2022. The company's five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with 50% derived from the U.S., 20% from Japan, 20% from Europe and Canada.

Takeda Pharmaceutical Co (SSE:4502) Headlines

No Headlines